Navigation Links
Proteolix Announces Clinical Results With Carfilzomib to be Reported at ASH 2007 Annual Meeting
Date:12/6/2007

SOUTH SAN FRANCISCO, Calif., Dec. 6 /PRNewswire/ -- Proteolix, Inc. announced today that data from two Phase 1 clinical studies using intravenous carfilzomib (PR-171) are to be presented at the 2007 American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia, December 8-10, 2007. Carfilzomib is a potent and selective proteasome inhibitor currently being investigated for the treatment of multiple myeloma, lymphoma and solid tumors.

Robert Z. Orlowski, M.D., Ph.D., of the University of Texas, M.D. Anderson Cancer Center, and Melissa Alsina, M.D., of the H. Lee Moffitt Cancer Center and Research Institute, will be presenting data from two Phase 1 clinical studies in relapsed and refractory hematologic malignancies on Monday, December 10 beginning at 11:00 am and 11:30 am EST, respectively, in a session entitled "Novel Therapies in Relapsed Myeloma." Additional information about the 2007 ASH Annual Meeting can be found on the ASH website at http://www.hematology.org/meetings/2007.

"We are very pleased that carfilzomib can be dosed on a consecutive-day schedule in humans, as was predicted by animal studies," said Susan M. Molineaux, Ph.D., President and CEO of Proteolix. "These early results showing single-agent activity in myeloma indicate the potential of this product candidate to help persons afflicted with the disease. We look forward to data throughout 2008 from ongoing Phase 1b and 2 studies in multiple myeloma, lymphoma and solid tumors."

About Proteolix

Proteolix, Inc. is a biopharmaceutical company dedicated to discovering, developing and marketing pharmaceutical products that target certain cancer and immunological conditions by inhibiting the proteasome and thereby disrupting protein turnover in cells. In addition to its lead product candidate, carfilzomib (PR-171), which is delivered intravenously and is currently in multiple clinical trials to evaluate its safety and efficacy in different types of cancer, Proteolix is developing next-generation proteasome inhibitors, including an oral proteasome inhibitor and a selective immunoproteasome inhibitor, to expand the therapeutic potential of this target class. Proteolix is headquartered in South San Francisco. For more information, please visit the Company's website at http://www.proteolix.com.

Contact: Stephen Brady, Executive Director of Business and Legal Affairs,

650-266-2621.


'/>"/>
SOURCE Proteolix, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
3. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
4. HEI, Inc. Announces Sale of RFID Division Assets
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
7. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
8. Brooke Franchise Corporation Announces Selected July Results
9. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... May 27, 2016 , ... With over 60 percent of acute stroke ... a sustainable product to aid in the rehabilitation process has steadily increased. Ekso Bionics ... individuals with hemiplegia due to stroke. , Ekso Bionics has now received clearance from ...
(Date:5/27/2016)... ... May 27, 2016 , ... Beleza Medspa ... fat composition regulations. This is the first time that Coolsculpting is being used ... least every six months to ensure they meet the prescribed body-fat standard, measured by ...
(Date:5/27/2016)... ... May 27, 2016 , ... ... in the pharmaceutical, medical and food industries. Aside from its GMP accreditation, Validation ... providing proof of successfully certified products, services and staff. , Validation Center is ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... of thousands of defective respirators, according to court documents and SEC filings. ... William and Becky Tyler v. American Optical Corporation, Case No. BC588866, Los Angeles ...
(Date:5/26/2016)... ... ... On Memorial Day, Hope For Heroes and USA Medical Card ... the country. The nonprofit Hope For Heroes partnered with the leading provider of ... disabled military veterans, as well as police, firemen, and EMS professionals across the country, ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... , May 25, 2016 As ... Expo earlier this month, the numbers and momentum of ... to climb into the billions, more research and development ... 4th Edition State of Legal Marijuana Markets Report  from ... data-analysis firm, much of the increase in sector is ...
(Date:5/25/2016)... PUNE, India , May 25, 2016 /PRNewswire/ ... Pipeline Review, H1 2016"market research report that provides ... complete with comparative analysis at various stages, therapeutics ... route of administration (RoA) and molecule type, along ... releases. It also reviews key players involved in ...
(Date:5/24/2016)...  Diana Russell suffers from a form of rheumatoid ... out.  This disease has put her in a wheelchair, ... grandchildren to leave her home.  Because of the size ... the wheelchair.  So if there is a family function, ... left to wait for the bus. Photo ...
Breaking Medicine Technology: